

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 12 of 12 returned.**

- 
- ☐ 1. [6149919](#). 25 Mar 97; 21 Nov 00. Immunogenic detoxified mutants of cholera toxin and of the toxin LT, their preparation and their use for the preparation of vaccines. [Domenighini](#); Mario, et al. 424/236.1; 424/184.1 424/234.1 424/240.1 424/241.1 424/257.1 424/261.1 435/69.3. A61K039/02 A61K039/108 A61K039/106 C12P021/06.
- 
- ☐ 2. [6039704](#). 25 Jun 98; 21 Mar 00. Head and facial massaging apparatus. [Domenighini](#); Pierluigi, et al. 601/79; 601/148 601/149 601/151 601/152. A61H001/00.
- 
- ☐ 3. [6036960](#). 01 Sep 94; 14 Mar 00. Filamentous hemagglutinin of B. pertussis. Relman; David A., et al. 424/253.1; 435/252.3 435/253.1 435/320.1 435/69.1 435/69.3 435/7.1 435/91.1 536/22.1 536/23.1 536/23.7 536/24.32. A61K039/10 G01N033/53 C12P021/06 C12P019/34.
- 
- ☐ 4. [JP02003000287A](#). 30 Dec 92. 07 Jan 03. IMMUNOGENIC DETOXICATED VARIANT OF CHOLERA TOXIN AND IMMUNOGENIC DETOXICATED VARIANT OF TOXIN LT, THEIR PREPARATION, AND THEIR USE FOR PREPARING VACCINE. DOMENIGHINI, MARIO, et al. C12N015/09; A61K038/00 A61K039/106 A61K039/108 A61P031/04 C07K014/245 C07K014/28 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12P021/02.
- 
- ☐ 5. [EP001484404A1](#). 30 Dec 92. 08 Dec 04. Immunogenic detoxified mutants of cholera toxin and of the toxin LT, their preparation and their use for the preparation of vaccines. DOMENIGHINI, MARIO, et al. C12N015/31; C12N001/21 C07K014/245 C07K014/28 A61K039/106 A61K039/108.
- 
- ☐ 6. [EP000869181A1](#). 30 Dec 92. 07 Oct 98. Immunogenic detoxified mutants of cholera toxin and of the toxin LT, their preparation and their use for the preparation of vaccines. DOMENIGHINI, MARIO, et al. C12N015/31; C12N001/21 C07K014/245 C07K014/28 A61K039/106 A61K039/108.
- 
- ☐ 7. [WO009313202A1](#). 30 Dec 92. 08 Jul 93. IMMUNOGENIC DETOXIFIED MUTANTS OF CHOLERA TOXIN AND OF THE TOXIN LT, THEIR PREPARATION AND THEIR USE FOR THE PREPARATION OF VACCINES. DOMENIGHINI, MARIO, et al. 530/350 536/23.7. A61K039/106; A61K039/108 C12N001/21 C12N015/00 C12N015/31 C12P021/02 C12R001/19.
- 
- ☐ 8. [WO009004641A1](#). 20 Oct 89. 03 May 90. FILAMENTOUS HEMAGGLUTININ OF B. PERTUSSIS. RELMAN, DAVID A, et al. 435/69.1 435/69.3 435/320.1 530/350 536/23.7. C12P021/00; C07H015/12 C07K013/00.
- 
- ☐ 9. [US 6039704A](#). Head and facial massaging apparatus for massaging facial tissue and occipital area of the scalp includes a support base constructed and arranged to contact a supporting surface. CLAPIS, M, et al. A61H001/00.
- 
- ☐ 10. [US 6036960A](#). New isolated nucleic acid encoding the filamentous hemagglutinin of Bordetella pertussis, useful for diagnosis, treatment and prevention of whooping cough. DOMENIGHINI, M, et al. A61K039/10 C12P019/34 C12P021/06 G01N033/53.
- 
- ☐ 11. [EP 620850B](#). Immunogenic detoxified mutant cholera toxin and heat labile toxin - useful as vaccines against infection by Vibrio cholerae and enterotoxin producing Escherichia coli. DOMENIGHINI, M, et al. A61K000/00 A61K038/00 A61K039/00 A61K039/02 A61K039/07

A61K039/08 A61K039/10 A61K039/106 A61K039/108 A61K039/38 A61P031/04 C07H021/04  
C07K001/00 C07K013/00 C07K014/00 C07K014/245 C07K014/28 C07K017/00 C12N001/021  
C12N001/15 C12N001/19 C12N001/20 C12N001/21 C12N005/10 C12N015/00 C12N015/000  
C12N015/031 C12N015/09 C12N015/10 C12N015/31 C12N015/63 C12N015/64 C12N015/70  
C12N015/74 C12P021/002 C12P021/02 C12P021/06 C12N001/21 C12R001:19 C12N001/21  
C12R001:19 C12N001/21 C12R001:19 C12N001/21 C12R001:19.

☐ 12. EP 439542B. Nucleic acid sequences encoding Bordetella pertussis FHA B gene - and peptide cross-reactive with filamentous haemagglutinin of B pertussis, useful for diagnosis and treatment of whooping cough. DOMENIGHINI, M, et al. A61K039/10 A61P031/00 C07H015/12 C07K013/00 C07K014/235 C12N001/20 C12N015/31 C12N015/62 C12P021/00.

[Generate Collection](#)[Print](#)

Term	Documents
DOMENIGHINI	53
DOMENIGHINIS	0
DOMENIGHINI.IN..PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	12
(DOMENIGHINI.IN.).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	12

[Prev Page](#)   [Next Page](#)   [Go to Doc#](#)

## WEST Search History





DATE: Tuesday, November 08, 2005

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L1	holotoxin.clm. or holo-toxin.clm. or ab5 or ab-5 or (ab near 5)	3540
<input type="checkbox"/>	L2	L1 and cholera	76
<input type="checkbox"/>	L3	holotoxin.ti,ab,clm. or holo-toxin.ti,ab,clm. or ab5.ti,ab,clm. or ab-5.ti,ab,clm. or (ab near 5).ti,ab,clm.	517
<input type="checkbox"/>	L4	L3 and (cholera or vibrio or ct or ctab or ct-a-b)	59
<input type="checkbox"/>	L5	chiron.asn. and cholera	140
<input type="checkbox"/>	L6	chiron.asn. and cholera\$	153
<input type="checkbox"/>	L7	L6 and (mutant or mutation or mutagenesis or modified or altered or deletion or substitution or insertion or addition or modification)	141
<input type="checkbox"/>	L8	L7 and (vibrio or ct or cholera).clm.	11
<input type="checkbox"/>	L9	l6 and portner.xa.	1
<input type="checkbox"/>	L10	l6 and domenighini	11
<input type="checkbox"/>	L11	domenighini.asn.	1
<input type="checkbox"/>	L12	domenighini.in.	12

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 50 of 59 returned.**

- 
- ☐ 1. [20050245437](#). 30 Dec 04. 03 Nov 05. Peptides having antimicrobial properties and compositions containing them, notably for the preservation of foodstuffs. Bulet, Philippe, et al. 514/9; 435/320.1 435/325 435/69.1 530/317 536/23.5 A61K038/12 C07K007/64.
- 
- ☐ 2. [20050208123](#). 24 Mar 05. 22 Sep 05. Chylamydia vaccine. Maisonneuve, Jean-Francois Lucien, et al. 424/450; 424/190.1 424/263.1 A61K039/02 A61K039/118 A61K009/127.
- 
- ☐ 3. [20050175631](#). 11 Apr 05. 11 Aug 05. Hiv vaccine and method of use. Vajdy, Michael, et al. 424/204.1; 435/69.1 530/300 C12P021/06 A61K039/12 C07K002/00 C07K004/00 C07K005/00 C07K007/00 C07K014/00 C07K016/00 C07K017/00 A61K038/00.
- 
- ☐ 4. [20050152922](#). 12 Nov 04. 14 Jul 05. Vaccines against escherichia coli O157 infection. Szu, Shousun Chen, et al. 424/236.1; 424/257.1 530/395 A61K039/02 A61K039/108 C07K014/245.
- 
- ☐ 5. [20050148538](#). 22 Feb 05. 07 Jul 05. Adjuvant formulations for bacterial and virus vaccines and method of making same. Hadden, John, et al. 514/45; 424/184.1 424/204.1 424/234.1 A61K031/7076 A61K039/00 A61K039/38 A61K039/12 A61K039/02.
- 
- ☐ 6. [20050074462](#). 26 Aug 04. 07 Apr 05. Supression of allergic reactions by transdermal administration of allergens conjugated to cholera toxin or fragments thereof. Holmgren, Jan, et al. 424/185.1; 424/235.1 424/449 A61K039/00 A61K009/70.
- 
- ☐ 7. [20040181036](#). 04 Dec 03. 16 Sep 04. Mutant forms of cholera holotoxin as an adjuvant. Green, Bruce A, et al. 530/350; A61K039/106 C07K001/00 C07K014/00 C07K017/00.
- 
- ☐ 8. [20040176571](#). 04 Dec 03. 09 Sep 04. Mutant forms of cholera holotoxin as an adjuvant. Green, Bruce A., et al. 530/350; A61K039/106 C07K001/00 C07K014/00 C07K017/00.
- 
- ☐ 9. [20040033229](#). 21 Mar 03. 19 Feb 04. PSMA antibodies and protein multimers. Maddon, Paul J., et al. 424/155.1; 435/7.23 530/388.8 G01N033/574 A61K039/395 C07K016/30.
- 
- ☐ 10. [20040028690](#). 24 Jan 03. 12 Feb 04. Nontoxic mucosal adjuvant. Rappuoli, Rino. 424/184.1; A61K039/00 A61K039/38 A61K039/02.
- 
- ☐ 11. [20040022760](#). 26 Mar 03. 05 Feb 04. Methods of using Flt3-ligand in immunization protocols. McKenna, Hilary J., et al. 424/85.1; 424/185.1 424/85.2 424/85.7 A61K039/00 A61K038/21 A61K038/19 A61K038/20.
- 
- ☐ 12. [20040009187](#). 24 Apr 03. 15 Jan 04. Rotavirus subunit vaccine. Choi, Anthony, et al. 424/186.1; 424/215.1 530/350 A61K039/12 A61K039/15 C07K014/14.
- 
- ☐ 13. [20030219453](#). 06 Nov 02. 27 Nov 03. Vaccines. Maisonneuve, Jean-Francois Lucien, et al. 424/190.1; 424/450 514/54 A61K039/02 A61K009/127 A61K031/739.
- 
- ☐ 14. [20030176653](#). 30 Dec 02. 18 Sep 03. Orally immunogenic bacterial enterotoxins expressed in transgenic plants. Mason, Hugh S., et al. 530/350; C07K001/00 C07K014/00 C07K017/00.
-

- 
- ☐ 15. 20030166139. 22 Jul 02. 04 Sep 03. Rotavirus VP6 subunit. Choi, Anthony H., et al. 435/69.1; 424/185.1 424/186.1 424/192.1 424/215.1 424/282.1 435/69.3 530/350 530/826 536/23.72 C07K014/14 A61K039/12 A61K039/15 C07H021/04 A61K045/00 C07K014/00 C12P021/06 C12N015/09 A61K039/00 C07K001/00 C07K017/00.
- 
- ☐ 16. 20030152593. 18 Dec 02. 14 Aug 03. Antiviral activity of shiga toxin. Bohach, Carolyn H., et al. 424/236.1; A61K039/02 A61K039/108.
- 
- ☐ 17. 20030113345. 19 Nov 02. 19 Jun 03. Hybrid lt-a/ct-b holotoxin for use as an adjuvant. Clements, John D. 424/203.1; 424/241.1 A61K039/116 A61K039/108.
- 
- ☐ 18. 20030072774. 07 Jun 95. 17 Apr 03. PROTEINACEOUS ADJUVANTS. GAJEWCZYK, DIANE M., et al. 424/254.1; A61K039/10.
- 
- ☐ 19. 20020187154. 04 Jun 02. 12 Dec 02. Nontoxic mucosal adjuvant. Rappuoli, Rino. 424/184.1; A61K039/00 A61K039/38.
- 
- ☐ 20. 6858211. 01 Aug 01; 22 Feb 05. Vaccines against Escherichia coli O157 infection. Szu; Shousun Chen, et al. 424/193.1; 424/184.1 424/192.1 424/195.11 424/197.11 424/234.1 424/236.1 424/240.1 424/244.1 424/251.1 424/258.1 424/725 424/9.2 530/403 530/404 530/405 530/406. A61K039/385.
- 
- ☐ 21. 6793928. 13 Dec 00; 21 Sep 04. Vaccines with an LTB adjuvant. van Scharrenburg; Gustaaf J. M., et al. 424/257.1; 424/193.1 424/197.11 424/201.1 424/209.1 424/236.1 424/241.1 435/69.1 530/350. A61K039/108.
- 
- ☐ 22. 6541013. 13 Jul 00; 01 Apr 03. Methods and compositions for suppressing bovine leukemia virus with a Shiga toxin polypeptide. Bohach; Carolyn H.. 424/241.1; 424/236.1 514/2. A61K039/108 A61K039/02 A61K038/00 A01N037/18.
- 
- ☐ 23. 6440423. 02 Aug 99; 27 Aug 02. Mutant enterotoxin effective as a non-toxic oral adjuvant. Clements; John D., et al. 424/236.1; 424/184.1 424/200.1 424/234.1 424/235.1 424/240.1 424/241.1 424/257.1 424/261.1 424/278.1 424/282.1 514/2 530/350 530/820 530/825. A61K039/02 A61K039/108 A61K039/106 A61K045/00 C07K001/00.
- 
- ☐ 24. 6436407. 04 Aug 99; 20 Aug 02. Mutant enterotoxin effective as a non-toxic adjuvant. Clements; John D., et al. 424/208.1; 424/184.1 424/200.1 424/234.1 424/235.1 424/236.1 424/278.1 424/282.1 530/350 530/825. A61K039/21 A61K039/02 A61K045/00 A61K039/00 A61K001/00.
- 
- ☐ 25. 6395964. 04 Aug 97; 28 May 02. Oral immunization with transgenic plants. Arntzen; Charles J., et al. 800/288; 424/186.1 424/257.1 424/261.1 435/320.1 435/419 435/468 435/69.3 800/287 800/298. C12N005/04 C12N015/82 C12N015/87 A01H005/00.
- 
- ☐ 26. 6197448. 15 Dec 97; 06 Mar 01. Hydrogen storage alloy. Gaydos; Mark, et al. 429/218.2; 29/623.1 420/900 429/223 429/224. H01M004/38 C01B006/24.
- 
- ☐ 27. 6168928. 21 May 98; 02 Jan 01. Modification of pertussis toxin. Read; Randy J., et al. 435/15; 435/18 435/193 435/195 435/69.1. C12N009/10 C12N009/14 C12N015/09 C12Q001/48 C12Q001/34.
- 
- ☐ 28. 6033673. 18 Mar 98; 07 Mar 00. Double mutant enterotoxin for use as an adjuvant. Clements;

John D.. 424/236.1; 424/184.1 424/241.1 424/278.1 424/282.1 424/832 424/9.2 514/885. A61K039/02 A61K039/108 A61K045/00 X61K039/00.

---

☐ 29. 6019982. 26 Aug 94; 01 Feb 00. Mutant enterotoxin effective as a non-toxic oral adjuvant. Clements; John D., et al. 424/236.1; 424/184.1 424/200.1 424/208.1 424/234.1 424/235.1 424/240.1 424/241.1 424/261.1 435/91.4. A61K039/00 A61K039/38 A61K039/02 C12N015/64.

---

☐ 30. 6018022. 06 Jun 95; 25 Jan 00. Modification of pertussis toxin. Read; Randy J., et al. 530/350; 424/240.1 424/254.1 435/252.33 435/320.1 435/69.1. C07K001/00 C12P021/06 A61K039/108 A61K039/10.

---

☐ 31. 5977304. 06 Jun 95; 02 Nov 99. Modification of pertussis toxin. Read; Randy J., et al. 530/350; 424/240.1 424/254.1 435/252.3 435/320.1 435/69.1 536/23.7. C07K001/00 C12P021/06 C12N001/20 C07H021/04.

---

☐ 32. 5965385. 06 Jun 95; 12 Oct 99. Modification of pertussis toxin. Read; Randy J., et al. 435/69.1; 424/240.1 424/254.1 435/252.3 435/320.1 530/350 536/23.7. C12P021/06 C12N001/20 C07H021/04 C07K001/00.

---

☐ 33. 5856122. 22 Aug 94; 05 Jan 99. Modification of pertussis toxin. Read; Randy J., et al. 435/69.1; 435/15. C12P021/02.

---

☐ 34. 5565297. 29 Aug 94; 15 Oct 96. Liquid developer compositions with oxygen containing copolymers. Larson; James R., et al. 430/115; 430/114 430/119 430/904. G03G009/135 G03G009/13.

---

☐ 35. 5552144. 10 Jan 94; 03 Sep 96. Immunogenic shiga-like toxin II variant mutants. Samuel; James E., et al. 424/236.1; 424/241.1 435/200 530/350 530/825. A61K039/108 C07K014/25 C07K014/245 C12N009/24.

---

☐ 36. 5433945. 20 Nov 92; 18 Jul 95. Immunoprotective genetically-detoxified mutants of pertussis toxin. Klein; Michel H., et al. 424/185.1; 424/190.1 424/240.1 530/350. A61K039/00 A61K039/02 A61K037/00 A01N063/00.

---

☐ 37. 5358868. 05 Nov 91; 25 Oct 94. Genetic detoxification of pertussis toxin. Klein; Michel H., et al. 435/69.1; 435/243 435/252.1 435/69.3 530/324 530/350 536/23.1 536/23.5. C12N001/00 C12N015/00 C12N001/12 C07K003/00.

---

☐ 38. 5332583. 05 Nov 91; 26 Jul 94. Vaccine containing genetically-detoxified pertussis holotoxin. Klein; Michel H., et al. 424/190.1; 424/200.1 424/240.1 435/252.1 435/252.3 530/350 530/387.9 530/390.1. C07K003/00 C12N001/20 A61K039/00 A61K039/02.

---

☐ 39. 5254427. 30 Dec 91; 19 Oct 93. Additives for liquid electrostatic developers. Lane; Gregg A., et al. 430/137.22; 430/114. G03G009/12.

---

☐ 40. 5244657. 28 Sep 90; 14 Sep 93. Genetic detoxification of pertussis toxin. Klein; Michel H., et al. 435/193; 424/190.1 424/240.1 424/832. A61K039/10.

---

☐ 41. 5221618. 30 Sep 91; 22 Jun 93. Genetic detoxification of pertussis toxin. Klein; Michel H., et al. 435/69.1; 435/252.1 435/477 435/69.3 536/23.7. C12P021/02 C12N015/01 C12N001/20 C07H021/00.

---

- ☐ 42. 5085862. 23 Nov 88; 04 Feb 92. Genetic detoxification of pertussis toxin. Klein; Michel H., et al. 424/197.11; 424/254.1 424/832 435/252.3 530/350 530/387.9 530/388.4 530/403 530/405 530/406 536/23.7. A61K039/02.
- 
- ☐ 43. 4605950. 20 Sep 83; 12 Aug 86. Two channel compatible high definition television broadcast system. Goldberg; Abraham A., et al. 348/389.1; 348/474. H04N009/42 H04N009/38.
- 
- ☐ 44. 4411888. 03 Jun 82; 25 Oct 83. Composition of a novel immunogen for protection against diarrheal disease caused by enterotoxigenic Escherichia coli. Klipstein; Frederick A., et al. 424/194.1; 424/197.11 424/236.1 424/241.1 424/257.1 424/261.1. A61K039/108 A61K039/106.
- 
- ☐ 45. WO2004083251A2. 11 Mar 04. 30 Sep 04. MUTANT CHOLERA HOLOTOXIN AS AN ADJUVANT AND AN ANTIGEN CARRIER PROTEIN. HAGEN, MICHAEL. C07K019/00; A61P031/00.
- 
- ☐ 46. WO002098369A2. 05 Jun 02. 12 Dec 02. MUTANT FORMS OF CHOLERA HOLOTOXIN AS AN ADJUVANT. GREEN, BRUCE A, et al. A61K00/;
- 
- ☐ 47. WO002098368A2. 05 Jun 02. 12 Dec 02. MUTANT FORMS OF CHOLERA HOLOTOXIN AS AN ADJUVANT. GREEN, BRUCE A, et al. A61K00/;
- 
- ☐ 48. WO002093998A2. 23 May 02. 28 Nov 02. SUPPRESSION OF ALLERGIC REACTIONS BY TRANSDERMAL ADMINISTRATION OF ALLERGENS IN CONJUNCTION WITH OR CONJUGATED TO TOXIN SUBUNITS OR FRAGMENTS THEREOF. HOLMGREN, JAN, et al. A61K038/16;.
- 
- ☐ 49. WO2004083251A. Immunogenic composition for immunizing mammalian host against cholera, Escherichia coli and pertussis, comprises a mutated cholera holotoxin subunit, Escherichia coli heat labile toxin, pertussis toxin and their covalent antigens. HAGEN, M. A61P031/00 C07K019/00.
- 
- ☐ 50. WO 200298369A. Novel immunogenic, mutant cholera holotoxin useful for enhancing immune response of vertebrate host to antigen, comprises amino sequence of subunit A of wild-type cholera toxin. GREEN, B A, et al. A61K000/00 A61K006/00 A61K039/00 A61K039/002 A61K039/008 A61K039/015 A61K039/02 A61K039/04 A61K039/05 A61K039/07 A61K039/08 A61K039/085 A61K039/09 A61K039/095 A61K039/10 A61K039/102 A61K039/106 A61K039/108 A61K039/112 A61K039/118 A61K039/12 A61K039/125 A61K039/13 A61K039/145 A61K039/15 A61K039/155 A61K039/165 A61K039/175 A61K039/20 A61K039/205 A61K039/21 A61K039/215 A61K039/23 A61K039/235 A61K039/245 A61K039/255 A61K039/265 A61K039/29 A61K039/35 A61K039/39 A61K039/42 C07K001/00 C07K014/00 C07K014/28 C07K017/00 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12P021/02.
- 

Generate Collection

Print

Term	Documents
CHOLERA	9962
CHOLERAS	26
VIBRIO	7806
VIBRIOS	252

CT	500768
CTS	68895
CTAB	3878
CTABS	5
CT-A-B	0
CT-A-BS	0
(3 AND (CT-A-B OR CTAB OR VIBRIO OR CHOLERA OR CT)).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	59
(L3 AND (CHOLERA OR VIBRIO OR CT OR CTAB OR CT-A-B)).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	59

[Prev Page](#)   [Next Page](#)   [Go to Doc#](#)



[Generate Collection](#)[Print](#)**Search Results - Record(s) 51 through 59 of 59 returned.**

- 
- ☐ 51. [WO 200298368A](#). Novel immunogenic mutant cholera holotoxin for preparing immunogenic composition for enhancing immune response of vertebrate host to bacterial or viral antigen, has reduced toxicity compared to wild-type cholera toxin. GREEN, B A, et al. A61K000/00 A61K039/00 A61K039/002 A61K039/008 A61K039/02 A61K039/095 A61K039/102 A61K039/106 A61K039/12 A61K039/245 A61K039/35 A61K039/39 A61K039/42 C07K001/00 C07K014/00 C07K014/28 C07K017/00 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12P021/02.
- 
- ☐ 52. [WO 200189456A](#). New hybrid heat labile enterotoxin of Escherichia coli and the B-subunit of the cholera enterotoxin of Vibrio cholerae, useful as adjuvants for vaccines, particularly for stimulating antibodies or cell mediated immune responses. CLEMENTS, J D. A61K000/00 A61K039/108 A61K039/116.
- 
- ☐ 53. [WO 200018434A](#). New mutant cholera holotoxin having a point mutation at amino acid position 29 of the A subunit useful as an adjuvant in an antigenic composition to enhance the immune response in a vertebrate host to a selected antigen from a pathogen. ELDRIDGE, J H, et al. A61K039/00 A61K039/002 A61K039/02 A61K039/095 A61K039/102 A61K039/106 A61K039/12 A61K039/15 A61K039/155 A61K039/245 A61K039/39 A61P037/04 C07K014/14 C07K014/22 C07K014/28 C07K014/285 C07K014:28 C12N001/15 C12N001/19 C12N001/21 C12N005/10 C12N015/09 C12N015/63 C12P021/02.
- 
- ☐ 54. [US 6033673A](#). A new mutant of Escherichia coli holotoxin useful as an adjuvant. CLEMENTS, J D. A61K039/00 A61K039/02 A61K039/108 A61K039/116 A61K039/295 A61K045/00 G01N033/53.
- 
- ☐ 55. [US 6436407B](#). Generating immune response to human immune deficiency virus antigen by mucosal delivery - using as adjuvant mutant, non-toxic form of E. coli holotoxin, raises both humoral and cellular responses. CLEMENTS, J D, et al. A61K000/00 A61K001/00 A61K039/00 A61K039/02 A61K039/106 A61K039/108 A61K039/21 A61K045/00 C12N015/00 C12N015/64.
- 
- ☐ 56. [WO 9828005A](#). Vaccine to prevent or treat Chlamydia trachomatis infection - contains outer membrane protein and mucosal adjuvant, is active at the mucosa and prevents infertility caused by infection. MAISONNEUVE, J L, et al. A61K000/00 A61K009/127 A61K039/02 A61K039/118 A61K039/39 A61P015/00 A61P031/04 A61K039/39 A61K039:118.
- 
- ☐ 57. [US 5552144A](#). New immunogenic mutant of Shiga-like toxin II variants - with reduced enzymatic activity and cytotoxicity, useful in vaccines against bacteria that cause oedema disease of swine. GORDON, V M, et al. A61K039/108 C07K014/245 C07K014/25 C12N009/24.
- 
- ☐ 58. [US 6019982A](#). Mutant E.coli heat-labile enterotoxin holo-toxin - useful as an immunological adjuvant in vaccines to create or sustain a protective or adaptive immune response in a host to a pathogen or antigen. CLEMENTS, J D, et al. A61K000/00 A61K038/00 A61K038/16 A61K039/00 A61K039/02 A61K039/106 A61K039/108 A61K039/38 A61K039/39 A61K045/00 C07K001/00 C07K014/195 C07K014/245 C12N015/00 C12N015/64 C12P021/02 C12P021/02 C12R001:19.
- 
- ☐ 59. [WO 8300018A](#). Vaccine against diarrhoeal diseases - contains conjugation prod. of heat stable- and heat labile enterotoxin. CLEMENTS, J, et al. A61F000/00 A61K039/10.
-

[Generate Collection](#)[Print](#)

Term	Documents
CHOLERA	9962
CHOLERAS	26
VIBRIO	7806
VIBRIOS	252
CT	500768
CTS	68895
CTAB	3878
CTABS	5
CT-A-B	0
CT-A-BS	0
(3 AND (CT-A-B OR CTAB OR VIBRIO OR CHOLERA OR CT)).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	59
(L3 AND (CHOLERA OR VIBRIO OR CT OR CTAB OR CT-A-B)).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	59

[Prev Page](#)   [Next Page](#)   [Go to Doc#](#)